AtaiBeckley Inc. (ATAI)

AtaiBeckley is a clinical-stage biotechnology company formed in 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. Its mission is to create breakthroughs for people with difficult-to-treat mental health conditions by developing rapid-acting, convenient treatments. It is building a diversified pipeline of investigational psychedelic-based neuroplastogens. On December 30, 2025, the company changed its corporate domicile from the Netherlands to the United States via Luxembourg, and AtaiBeckley Inc., a Delaware corporation, became the successor issuer.

The pipeline consists of wholly owned product candidates. BPL-003 is a dry powder nasal spray of mebufotenin (5-MeO-DMT) benzoate for treatment-resistant depression (TRD). It has completed a Phase 2b double-blind study with an open-label extension, and a Phase 2a study is ongoing. After an End-of-Phase 2 meeting with the FDA in February 2026, the company plans two pivotal Phase 3 trials, ReConnection 1 and ReConnection 2, to begin in the second quarter of 2026. VLS-01 is a proprietary buccal film formulation of DMT for TRD, with a Phase 2 trial (Elumina) started in March 2025 and topline results expected in the second half of 2026. EMP-01 is an oral formulation of R-MDMA for social anxiety disorder. The company also runs a drug discovery program seeking novel, non-hallucinogenic 5-HT2A receptor agonists for TRD and opioid use disorder. Intellectual property development has been a key strategic component since inception.

The company targets mental health disorders, which it says affect more than one billion people globally. It focuses on patients with TRD, a group it says makes up about 50% of the estimated 300 million people with depression worldwide, and on social anxiety disorder and opioid use disorder. It cites an unmet need because roughly 65% of patients do not reach remission after up to four antidepressant trials with existing therapies such as SSRIs, SNRIs and Spravato. It positions BPL-003 to fit the roughly two-hour in-clinic interventional psychiatry treatment model established by Spravato. The text provides no information on commercial revenue or customers.

The text does not describe suppliers, manufacturing, competitors or headquarters location. It does say that the company conducts clinical trials across multiple sites and countries, including a Phase 2b study run at 38 sites in six countries.